Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Molecular Pharmaceutics|January 19, 2017
Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of EfficacyTheodoros Karampelas, Eleni Skavatsou, Orestis Argyros, et al.Cancers|April 30, 2021
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLCEleni Skavatsou, Maria Semitekolou, Ioannis Morianos, et al.Cardiovascular and Interventional Radiology|April 12, 2024
Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular CarcinomaMiltiadis Krokidis, Danae Fakitsa, Katerina Malagari, et al.Journal of Medicinal Chemistry|December 30, 2021
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of GemcitabineTheodora Chatzisideri, George Leonidis, Theodoros Karampelas, et al.Materials Science & Engineering. C, Materials for Biological Applications|June 21, 2017
Versatile quarto stimuli nanostructure based on Trojan Horse approach for cancer therapy: Synthesis, characterization, in vitro and in vivo studiesEleni K Efthimiadou, Eirini Fragogeorgi, Lazaros Palamaris, et al.European Journal of Medicinal Chemistry|May 25, 2019
Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacyEfthymios-Spyridon Gavriil, Aris Doukatas, Theodoros Karampelas, et al.European Journal of Medicinal Chemistry|February 5, 2019
Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profileNisar Sayyad, Eirinaios I Vrettos, Theodoros Karampelas, et al.European Journal of Medicinal Chemistry|November 23, 2020
Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancerEirinaios I Vrettos, Theodoros Karampelas, Nisar Sayyad, et al.Oncotarget|April 20, 2017
Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small moleculeOrestis Argyros, Theodoros Karampelas, Aimilia Varela, et al.Cancer Research|December 10, 2015
Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor GrowthOrestis Argyros, Theodoros Karampelas, Xenophon Asvos, et al.Pageof 2